| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 432,508 | 397,712 | ||
| Marketable securities | 49,576 | 49,549 | ||
| Accounts receivable, net | 43,779 | 49,977 | ||
| Other receivables | 52,813 | 69,090 | ||
| Inventory | 61,956 | 68,968 | ||
| Prepaid expenses and other current assets | 19,195 | 20,365 | ||
| Total current assets | 659,827 | 655,661 | ||
| Property and equipment, net | 232,534 | 239,710 | ||
| Restricted cash | 201 | - | ||
| Operating lease right-of-use assets | 63,650 | 62,700 | ||
| Goodwill | 4,511 | 4,511 | ||
| Intangible assets, net | 64,759 | 14,714 | ||
| Other noncurrent assets | 1,879 | 2,674 | ||
| Total assets | 1,027,361 | 979,970 | ||
| Accounts payable | 18,069 | 15,938 | ||
| Accrued compensation and related benefits | 37,084 | 26,102 | ||
| Accrued expenses and other current liabilities | 35,766 | 39,063 | ||
| Deferred revenue | 22,139 | 21,449 | ||
| Operating lease liabilities | 10,543 | 9,669 | ||
| Contingent consideration, current | 23,723 | - | ||
| Total current liabilities | 147,324 | 112,221 | ||
| Contingent consideration, noncurrent | 1,210 | - | ||
| Operating lease liabilities, noncurrent | 76,442 | 77,075 | ||
| Deferred revenue, noncurrent | 10,871 | 11,270 | ||
| Other noncurrent liabilities | 6,394 | 6,125 | ||
| Total liabilities | 242,241 | 206,691 | ||
| Preferred stock | 0 | 0 | ||
| Common stock | 2 | 2 | ||
| Additional paid-in capital | 2,279,319 | 2,239,924 | ||
| Accumulated deficit | -1,494,339 | -1,466,867 | ||
| Accumulated other comprehensive income (loss) | 138 | 220 | ||
| Total stockholders equity | 785,120 | 773,279 | ||
| Total liabilities and stockholders equity | 1,027,361 | 979,970 | ||
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)